clinical trial · NCT07451054
CD45BE-HSPC + CART-45 Cells
B-Cell Non-Hodgkin Lymphoma (NHL)Richter's TransformationT-Cell Non-Hodgkin LymphomaHodgkin LymphomaCART-45 cellsCD45BE-HSPC
brief summary
This is a phase 1, open-label, dose-finding study to assess the safety, feasibility, pharmacokinetics and preliminary efficacy of autologous base edited anti-CD45 CAR T cells (referred to as "CART-45 cells") following an autologous transplant of CD45 base edited hematopoietic stem and progenitor cells (referred to as "CD45BE-HSPC") in patients with relapsed or refractory hematologic malignancies.
started
Apr 1, 2026
primary completion
Apr 1, 2043
completion
Apr 1, 2043
last updated
Mar 5, 2026
official title
Phase 1 Study of Autologous Anti-CD45 CAR T Cells in Combination With CD45 Base Edited HSPCs in Patients With Relapsed or Refractory Hematologic Malignancies
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol